YAFO Capital
YAFO Capital describes a platform combining life-sciences transaction advisory, licensing, fundraising, principal investment, NewCo incubation, and cross-border partnering activities.
What stands out about YAFO Capital
YAFO Capital publicly describes advisory services spanning licensing, M&A, fundraising, buy-side research, commercial assessment, pipeline strategy, transaction execution, and cross-border business development. Its NewCo Hub also states that YAFO invests in innovative biopharmaceutical assets and supports strategic partnerships, R&D financing, company building, and eventual licensing, M&A, or other strategic transactions.[1][2][3][4]
What does YAFO Capital do?
YAFO Capital is headquartered in Shanghai and describes itself as a boutique investment and advisory platform focused on cross-border transactions and global innovation partnerships in life sciences.
Its public business description combines transaction advisory and consulting with principal investment, NewCo incubation, and industry-partnering activities. The platform also identifies YAFO Fund, the YAFO NewCo Hub, and ACCESS ASIA as parts of its operating model.[1][4]
YAFO publicly states that it provides asset licensing, M&A, fundraising, buy-side research, commercial assessment, and pipeline-strategy services for global and Asian biopharma and medtech companies.
YAFO Life Sciences describes buy-side asset research and in-licensing, sell-side business development and out-licensing, transaction advisory and execution support, commercial assessment, and pipeline-strategy consulting. Its transaction support includes strategy, competitive-process design, deal-structure advice, commercial-term analysis, due-diligence coordination, and multi-party negotiation.[1][2]
Owners comparing advisory firms can also review Auxo’s M&A advisor vs. business broker vs. investment bank comparison, advisor-selection guide, and sell-side advisor evaluation framework.
What should a business owner evaluate before hiring YAFO Capital?
YAFO’s stated sell-side out-licensing, business-development, cross-border transaction, commercial-assessment, and execution capabilities may be relevant to an owner evaluating a life-sciences strategic transaction. Its NewCo Hub also describes investment in innovative biopharmaceutical assets and support for strategic partnerships, R&D financing, company building, and eventual licensing, M&A, or other strategic transactions.
An owner should clarify whether YAFO would act solely as advisor, invest directly, represent a counterparty, or participate through a fund or NewCo structure. The engagement should also establish the contracting entity, any affiliated or fund roles, conflicts procedures, fee mechanics, exclusivity, termination rights, and the applicable mandate criteria.[2][4]
What are the proposed fee mechanics, minimum fees, expense reimbursement, tail period, exclusivity, termination rights, and conflicts procedures
What size transactions and clients does YAFO Capital focus on?
YAFO states that its work spans life sciences, including biopharma, pharmaceuticals, biotech, medtech, and medical devices. Publicly named therapeutic and technology areas include oncology, ophthalmology, metabolic diseases, orthopedics, immunology, medical devices, and other therapeutic and technology areas.[1][2]
The official News archive identifies a collaboration between CrystalO and Almirall for discovery and development of novel small molecules in medical dermatology, dated August 10, 2026. It also identifies The United Laboratories’ exclusive license agreement with Novo Nordisk for UBT251, dated March 24, 2025; EnitiateBio and Joincare’s licensing agreement for QY101 inhalation, dated December 3, 2024; and Alphamab Biopharma and 3DMedicines’ licensing agreement with Glenmark for KN035, dated January 25, 2024.
The archive states that KiOmed Pharma licensed KiOmedinevsOne development and commercialization rights to Hansoh Pharma for mainland China, Macau, and Taiwan, with potential upfront and milestone payments of up to €66 million plus double-digit royalties on future product sales.[3]
YAFO’s stated transaction focus includes licensing, co-development, M&A, fundraising, and financing transactions. Its advisory materials describe work on both buy-side asset research and in-licensing and sell-side business development and out-licensing.
The stated support covers transaction strategy, process design, deal-structure advice, commercial-term analysis, diligence coordination, negotiation, and execution support.[1][2]
What does YAFO Capital publicly disclose about fees, process and engagement terms?
The cited About page does not state minimum revenue, EBITDA, enterprise-value, transaction-size, or client-size thresholds.
The cited NewCo Hub page states that YAFO has been a licensed fund manager since 2015 but does not identify the licensing regulator, license number, or legal entity holding the authorization.
The cited official News archive identifies transactions and selected deal terms in some entries but does not provide a consistent fee schedule or complete consideration details for every listed transaction.[1][3][4]
YAFO’s official NewCo Hub page states that YAFO has been a licensed fund manager since 2015 and has managed multiple investment funds.
The cited NewCo Hub page does not identify the licensing regulator, license number, or legal entity holding the authorization.[4]
YAFO Life Sciences describes a process that includes asset screening, target prioritization, outreach, due diligence, negotiation, and execution support. The stated transaction-support activities also include competitive-process design, deal-structure advice, commercial-term analysis, and multi-party negotiation.[2]
Questions to ask before hiring YAFO Capital
Which legal entity would sign the engagement, and which entity, if any, would invest or hold assets?
Would YAFO act exclusively for the seller, and could YAFO, an affiliate, fund, or partner also be a potential investor or counterparty?
What are the proposed fee mechanics, minimum fees, expense reimbursement, tail period, exclusivity, termination rights, and conflicts procedures?
What transaction-size, asset-stage, geography, or therapeutic-area criteria apply to the mandate?
If a fund or NewCo is involved, what is the fund vehicle, regulatory or licensing basis, investment mandate, decision process, and expected ownership or exit approach?
Which team members would lead the engagement, and can YAFO provide references for comparable transactions in the relevant indication or technology area?
Sources & research notes
- Official website / firm overview
- Services / capabilities
- Transaction / portfolio evidence
- Investment strategy
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.